Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people ...

The review emphasizes how breakthroughs in understanding the molecular mechanisms of cell cycle regulation have paved the way for the development of targeted anti-cancer agents. Notably, inhibitors of ...

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to ...

“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat ...

A new study published today in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer ...

Rb1 loss may serve as a predictive biomarker to guide new targeted therapies for select breast cancers resistant to standard ...